News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Earnings
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have investors contemplating their next move. Is there a buying opportunity in Gilead Sciences, or does it present a …
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Summit Global Investments initiated a new position in Gilead Sciences, acquiring 11,712 shares valued at $1.48 million during the second quarter. Gilead Sciences reported strong Q2 earnings, surpassing revenue and EPS expectations, with a 10.6% year-over-year revenue increase and declared a quarterly dividend of …
Centric Wealth Management has acquired a new stake of 26,506 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $3.52 million during the second quarter. This move is part of broader institutional interest, with 83.67% of Gilead's stock owned by institutional investors and hedge …
Cornerstone Capital Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 36,158 shares valued at approximately $4.57 million during the second quarter. This move comes as institutional investors and hedge funds collectively own 83.67% of the company. Gilead recently reported stronger-than-expected quarterly …
Abundance Wealth Counselors significantly increased its stake in Gilead Sciences, Inc. by 93.7% in the second quarter, now holding 22,139 shares valued at $2.8 million. This comes as Gilead reported strong Q2 revenue growth of 10.6% to $7.8 billion, driven by its HIV franchise …
Gildan Activewear (TSE:GIL) shares recently fell below their 200-day moving average, trading at C$78.75 compared to the C$81.55 average. Despite this, analysts maintain a "Moderate Buy" consensus with an average price target of C$89.50. The company also declared a quarterly dividend of C$0.249, yielding …
Wall Street Zen has downgraded Ermenegildo Zegna (NYSE:ZGN) from a "buy" to a "hold" rating, contributing to a mixed analyst sentiment with an overall "Hold" consensus and an average price target of $13.13. Despite this, other analysts like TD Cowen, UBS Group, and JPMorgan …
Wall Street Zen has upgraded Gilead Sciences (NASDAQ:GILD) from a "Hold" to a "Buy" rating. This upgrade aligns with a "Moderate Buy" consensus among analysts, with an average price target of $158.04. The company recently reported strong quarterly results, exceeding revenue expectations, despite some …
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Caisse de dépôt et placement du Québec has reported a 6.3% ownership stake in Gildan Activewear Inc. (GIL), holding 11,679,294 common shares. This information comes from a SCHEDULE 13G/A filing, indicating that Caisse de dépôt et placement du Québec possesses sole voting and dispositive …
Gilead Sciences (GILD) is gaining investor attention due to a new AI collaboration with Nucleai and positive Q2 results, though some analyses suggest it might be overvalued by about 8%. The company is transitioning into a multi-platform biopharma, but differing valuation models present varied …
A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …
Gildan Activewear Inc. (GIL) shares fell by 0.87% on Friday, closing at C$78.75. This performance underperformed the broader Canadian market, as the S&P/TSX Composite Index (GSPTSE) only declined by 0.08%. The company's stock is now 21.6% below its 52-week high of C$100.44, achieved on …
Sharemaestro market context Price below Trend Line 52 weeks +3.5% · Next-week setup positive 56.7%Mirae Asset Global Investments Co. Ltd. increased its stake in Gilead Sciences by 10.9% in the second quarter, now holding 926,242 shares valued at $117 million. This move comes as Gilead reported strong quarterly revenue of $7.80 billion, exceeding analyst expectations, and announced a …
Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …
Gildan Activewear Inc. has added HBI Branded Apparel Enterprises, LLC, Hanes Jiboa Holdings LLC, and Hanesbrands El Salvador, Ltda. de C.V. as new guarantors for its $600 million 4.700% Notes due 2030 and $600 million 5.400% Notes due 2035. This action, formalized through a …
Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding …
Gildan Activewear Inc. (NYSE: GIL) is currently under multiple securities-law investigations initiated after a short seller's report questioned the company's revenue growth, distributor inventory levels, and sales practices. Several law firms are looking into potential securities fraud allegations, particularly concerning "channel stuffing," while Gildan …
This article provides a detailed analysis of Ermenegildo Zegna N.v. (ZGN), highlighting weak near-term sentiment but strong long-term prospects. It outlines specific institutional trading strategies including long, breakout, and short positions with entry zones, targets, and stop losses. The analysis also incorporates multi-timeframe signal …
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …
BNP Paribas has initiated coverage on Ermenegildo Zegna NV (ZGN.US) with a "Sell" rating. The firm has set a target price of $12.2 for the luxury fashion company's stock.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gilead Sciences has partnered with Nucleai for an AI-powered biomarker research collaboration aimed at improving precision oncology and supporting Gilead's antibody drug conjugate clinical programs. This initiative seeks to standardize biomarker analyses in clinical trials to develop more tailored cancer treatments. The collaboration comes …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …
Sharemaestro market context Price above Trend Line 52 weeks +42.5% · Next-week setup positive 55.2%Gildan Activewear Inc. (GIL) shares dropped 1.96% on Wednesday, closing at C$79.90, despite a generally favorable trading session for the Canadian market. The S&P/TSX Composite Index rose 0.51% to 36,662.14. Gildan's stock is now 20.5% below its 52-week high of C$100.44 reached on February …
Strategic Holding Group S.a r.l., a Luxembourg entity, has reported a beneficial ownership of 22,568,556 ordinary shares in Ermenegildo Zegna N.V. This stake represents 8.41% of the outstanding shares, based on 268,312,050 shares as of March 6, 2026. The filing indicates that Strategic Holding …
Wedge Capital Management L L P NC increased its stake in Gildan Activewear, Inc. by 14% during the second quarter, bringing its total holdings to 613,324 shares valued at $31.6 million. This move is part of broader institutional interest, with major investors like Janus …
Sharemaestro market context Price below Trend Line 52 weeks +3.5% · Next-week setup positive 56.7%Erste Group Bank has lowered its FY2026 EPS forecast for Gilead Sciences to a loss of $0.75 per share, below the consensus estimate of a $0.50-per-share loss. Despite this, analyst sentiment remains a "Moderate Buy" with an average price target of $158.04. Gilead reported …
Search by ticker symbol or company name and select a result to open its chart.